Stress testing of crisaborole by a novel stability indicating RP-HPLC method
Tóm tắt
An isocratic reverse phase high performance liquid chromatographic method has been developed for the determination of crisaborole (CRB), a novel non-steroidal topical phosphodiesterase-4-inhibitor. The analyte was separated on an Agilent eclipse XDB-C18 (3.0 × 150 mm, 3.5 µm) analytical column using water: acetonitrile (30: 70 v/v) as the mobile phase at a flow rate of 0.75 ml/min under ambient temperature and PDA detection at 254 nm. Added to this, several validation parameters were exercised on the developed HPLC method as per ICH guidelines. Method variables, viz., mobile phase flow rate (0.75 ± 0.1 ml/min) and percentage of organic modifier in mobile phase (70 ± 5%) were studied by a central composite design for testing the robustness of the proposed method. The method was found to be linear in the concentration range of 2–100 µg/ml (r2 = 0.999) and precise (RSD ˂ 2%) satisfying regulatory criteria. The method was found to be robust and ambiguity of worst result for certain responses still are acceptable and likely to occur due to the effect of extreme experimental conditions. Stress testing of CRB was carried out under acid, base, thermal, photolysis, peroxide and neutral conditions. Separation of the forced degradation products from the main analyte was accomplished using a gradient elution of the mobile phase consisting acetonitrile from 0 to 100% in water at a flow rate of 1.2 ml/min.
Tài liệu tham khảo
Hussar DA, Lee Y (2017) Crisaborole, dupilumab, and sarilumab. J Am Pharm Assoc 57:640–643
Kailas A (2017) Crisaborole: a new and effective nonsteroidal topical drug for atopic dermatitis. Dermatol Ther 30:e12533
Paller AS, Tom WL, Call RS, Eichenfield L, Forsha D, Rees WC, Zane LT, Hebert AA (2016) Phase 3 studies in atopic dermatitis with the novel, nonsteroidal topical phosphodiesterase 4 inhibitor, crisaborole. J Invest Dermatol. https://doi.org/10.1016/j.jid.2016.02.316
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75:494–503
Eichenfield LF, Call RS, Forsha DW, Fowler J, Hebert AA (2017) Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol 77:641–649
Ciaravino V, Coronado D, Lanphear C, Chanda S (2017) 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis. J Dermatol Sci 87:116–122
Lee EB, Lebwohl MG, Wu JJ (2019) Treatment of psoriasis with crisaborole. J Dermatol Treat 30:156–157
Simpson EL, Paller AS, Boguniewicz M, Eichenfield LF, Feldman SR, Silverberg JI, Chamlin SL, Zane LT (2018) Crisaborole ointment improves quality of life of patients with mild to moderate atopic dermatitis and their families. Dermatol Ther 8:605–619
Demurtas A, Pescina S, Nicoli S, Santi P, Padula C (2019) Development and validation of a simple method for the extraction and quantification of crisaborole in skin layers. Biomed Chromatogr 33:e4664. https://doi.org/10.1002/bmc.4664
Sahu PK, Rao RN, Cecchi T, Swain S, Patro CS, Panda J (2018) An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 147:590–611
Sahu PK (2017) Determination of system suitability limits with a robustness test. J Anal Bioanal Tech 8:363–370
Sahu PK, Panda J, Jogendra Kumar YVV, Karunya SR (2020) A robust RP-HPLC method for determination of turmeric adulteration. J Liq Chromatogr Relat Technol. https://doi.org/10.1080/10826076.2020.1722162
Vander Heyden Y, Jimidar M, Hund E, Niemeijer N, Peeters R, Verbeke JS, Massart DL, Hoogmartens J (1999) Determination of system suitability limits with a robustness test. J Chromatogr A 845:145–154